Stockscreener 앱 받기
0.3055
2.86%
0.0085
시간 외 거래:
.29
-0.0155
-5.07%
전일 마감가:
$0.297
열려 있는:
$0.3
하루 거래량:
559.39K
Relative Volume:
0.02
시가총액:
$8.47M
수익:
$94,000
순이익/손실:
$-13.28M
주가수익비율:
-0.0419
EPS:
-7.2965
순현금흐름:
$-11.67M
1주 성능:
+7.57%
1개월 성능:
-40.77%
6개월 성능:
-76.29%
1년 성능:
-96.54%
1일 변동 폭
$0.285
$0.3055
1주일 범위
$0.279
$0.3083
52주 변동 폭
$0.21
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
명칭
AIM ImmunoTech Inc
전화
352 448 7797
주소
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.3055 | 8.23M | 94,000 | -13.28M | -11.67M | -7.2965 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
AIM ImmunoTech Inc 주식(AIM)의 최신 뉴스
AIM ImmunoTech spotlights pancreatic cancer program progress in CEO video - Stock Titan
Why Did AIM Stock Plummet 35% Today? - Stocktwits
AIM ImmunoTech(AIM) Stock Options Chain | Quotes & News - Moomoo
AIMAIM ImmunoTech Inc Latest SEC Filings - Finviz
AIM Should I Buy - Intellectia AI
Price to sales forward of AIM ImmunoTech Inc. – MUN:HXB - TradingView
Enterprise value to EBIT forward of AIM ImmunoTech Inc. – AMEX:AIM - TradingView
Enterprise value to EBITDA forward of AIM ImmunoTech Inc. – AMEX:AIM - TradingView
Enterprise value to EBITDA forward of AIM ImmunoTech Inc. – MUN:HXB - TradingView
Enterprise value to revenue forward of AIM ImmunoTech Inc. – AMEX:AIM - TradingView
Enterprise value to revenue forward of AIM ImmunoTech Inc. – MUN:HXB - TradingView
Price to earnings forward of AIM ImmunoTech Inc. – MUN:HXB - TradingView
AIM ImmunoTech Inc. Actuals & Estimates (FWB:HXB) - TradingView
AIM ImmunoTech Inc. Actuals & Estimates (AMEX:AIM) - TradingView
AIM Forecast — Price Target — Prediction for 2027 - TradingView
AIM ImmunoTech (NYSE: AIM) seeks approval for major warrant financings and up to 1-for-25 reverse split - Stock Titan
AIM ImmunoTech (AIM) registers 13.08M shares for resale after June Offering - Stock Titan
AIM ImmunoTech Company Profile & Introduction - Moomoo
AIM ImmunoTech outlines pancreatic cancer trial milestones By Investing.com - Investing.com South Africa
AIM ImmunoTech outlines pancreatic cancer trial milestones - Investing.com
AIM ImmunoTech Accelerates Toward Potential Pivotal - GlobeNewswire
AIM ImmunoTech’s pancreatic cancer study hits a key milestone - Stock Titan
[EFFECT] AIM ImmunoTech Inc. SEC Filing - Stock Titan
AIM ImmunoTech Q1 2026 Earnings: Wider-Than-Expected Loss as Company Continues Clinical ProgressManagement Tone Analysis - dars.gov.et
AIM ImmunoTech Inc (AIM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series - The Manila Times
AIM News | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM ImmunoTech (NYSE American: AIM) resale of 31.3M warrant‑related shares - Stock Titan
AIM ImmunoTech (AIM) News, Articles, Events & Latest Updates - Stocktwits
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer - The Manila Times
Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders - TradingView
AIM ImmunoTech clears final dose milestone in pancreatic cancer trial - Stock Titan
AIM ImmunoTech Achieves Clinical Milestone as Final Subject - GlobeNewswire
AIM ImmunoTech (NYSE: AIM) registers 13.1M shares for resale in June deals - Stock Titan
AIM ImmunoTech Inc (AIM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AIM ImmunoTech Inc (AIM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AIM ImmunoTechFiles to Offer and Resell up - Moomoo
AIM ImmunoTech Inc (AIM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AIM ImmunoTech Inc (AIM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AIM ImmunoTech Inc (AIM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AIM ImmunoTech Inc (AIM) Institutional Confidence - TradingKey
AIM ImmunoTech Inc (AIM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AIM ImmunoTech Inc (AIM) Valuation: PE, PB & Fair Value Analysis - TradingKey
AIM ImmunoTech Regains NYSE American Listing Compliance - The Globe and Mail
AIM ImmunoTech (AIM) seeks approvals to issue >19.99% shares, reverse split option - Stock Titan
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - The Manila Times
AIM Regains NYSE American Compliance After Equity-Boosting Financings - TradingView
AIM ImmunoTech (NYSE: AIM) lifts equity, regains NYSE American listing standards - Stock Titan
NYSE lifts compliance tag on AIM ImmunoTech after new equity financings - Stock Titan
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
AIM ImmunoTech Announces $2.65 Million At-Market Financing to Advance Clinical Trials and Drug Development 1 - Minichart
AIM ImmunoTech Inc (AIM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
2.48%
자본화:
|
볼륨(24시간):